Zhongchao Inc. (ZCMD) 주식 분석
의료Zhongchao Inc.
$1.45
+$0.02 (+1.40%)
최종 업데이트: 2026년 5월 26일
가격 추이
가격 데이터가 없습니다
분석
회사 개요
Zhongchao Inc. operates within the Healthcare sector, specifically focusing on the Health Information Services industry, where it delivers specialized information, education, and training solutions to healthcare professionals primarily through its MDMOOC brand in the People's Republic of China. The company's operational scope encompasses two distinct business segments, namely MDMOOC services and the Sales of Patented Drugs, alongside offering patient management services to support its core mission. In terms of market scale, Zhongchao Inc. currently holds a market capitalization of $7.42M and generates annual revenue of $11.37M, while the available data indicates an employee count marked as N/A. These valuation and revenue figures suggest that the company functions as a small-cap entity with limited market penetration, operating with a relatively modest financial footprint compared to larger industry peers.
재무 건전성
The company reported a revenue of $11.37M over the trailing twelve months, yet it posted a net income of $-6,310,153 and an EBITDA of $-5,901,042, revealing a significant gap between top-line growth and profitability that highlights a highly aggressive or inefficient cost structure where operating expenses far exceed earnings before interest and taxes. The free cash flow stands at $-1,112,632, which indicates that the company is burning cash rather than generating liquidity, thereby limiting its financial flexibility and reliance on external funding sources to sustain operations. Profitability is further eroded by a gross margin of 45.0%, which is moderately healthy for the sector, but this is severely offset by an operating margin of -92.0% and a profit margin of -55.5%, signaling that overhead costs and operational inefficiencies are the primary drivers of the loss. Regarding liquidity and leverage, the company holds $13.92M in cash against a debt level of $26,083, resulting in a debt-to-equity ratio of 0.12 that characterizes a conservative balance sheet with minimal leverage. This strong cash position is reinforced by a current ratio of 11.11, which indicates an exceptional ability to meet short-term obligations and suggests robust short-term liquidity despite the operating losses. Furthermore, the return on equity is -24.9% and the return on assets is -15.5%, metrics that reveal management has not yet achieved positive capital efficiency and is currently destroying value relative to the shareholders' equity and total asset base.
밸류에이션 평가
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's negative earnings, meaning traditional earnings-based valuation multiples cannot be applied to assess the expected earnings trajectory or future profitability expectations. Instead, investors must rely on asset-based metrics, such as the price-to-book ratio of 0.30, which indicates that the stock is trading at a significant discount to its book value, suggesting the market does not expect a near-term recovery in book value per share. Alternative valuation metrics like the price-to-sales ratio of 0.65 and an EV/EBITDA of 0.42 provide a clearer picture of value, implying the company is priced based on revenue and enterprise value relative to earnings power rather than current profitability. The stock's price volatility is defined by a 52-week high of $12.18 and a 52-week low of $1.44, and while the current price is not explicitly listed, the wide range suggests the asset has experienced substantial price swings, though the beta value is N/A preventing a direct comparison to broader market volatility. These valuation parameters collectively point to a deep discount relative to historical highs, though the lack of a beta metric limits the assessment of systematic risk relative to the overall market index.
Growth & Income
The revenue growth year-over-year is -23.2%, while earnings growth is N/A given the negative net income, indicating that the company is currently contracting in terms of sales and has not yet demonstrated a trajectory toward positive earnings growth. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as the dividend yield is N/A and the payout ratio is 0.0%, which implies that any potential earnings would theoretically be reinvested into growth initiatives rather than distributed to shareholders, although the current negative earnings preclude actual payouts. The overall growth and income profile for Zhongchao Inc. is characterized by a contraction in revenue, a complete absence of cash dividends, and a valuation structure that relies on asset backing rather than earnings power or dividend income.
동종업체 비교
Zhongchao Inc. (ZCMD) 은(는) 의료 정보 서비스 산업에서 운영됩니다. 시가총액 기준으로 가장 가까운 동종업체와의 비교는 다음과 같습니다:
| 기업명 | 티커 | 시가총액 | PER |
|---|---|---|---|
| Zhongchao Inc. | ZCMD | $5.59M | N/A |
| Veeva Systems Inc. | VEEV | $25.87B | 29.1 |
| BrightSpring Health Services, Inc. | BTSG | $11.70B | 78.3 |
| Tempus AI, Inc. | TEM | $8.38B | N/A |
의료 정보 서비스 산업 평균 PER은 57.5배입니다. Zhongchao Inc.의 PER은 N/A입니다.
이 분석은 AI가 생성한 것으로 정보 제공 목적으로만 사용되며 투자 조언이 아닙니다. 데이터가 지연되거나 부정확할 수 있습니다. 투자 결정을 내리기 전에 항상 직접 조사하고 자격을 갖춘 재무 상담사와 상담하세요.
관련 의료 정보 서비스 종목
Veeva Systems Inc.
$25.87B
BTSGBrightSpring Health Services, Inc.
$11.70B
TEMTempus AI, Inc.
$8.38B
HQYHealthEquity, Inc.
$7.31B
HNGEHinge Health, Inc.
$4.10B
WAYWaystar Holding Corp.
$3.78B
의료 인기 주식
Eli Lilly and Company
$949.47B
JNJJohnson & Johnson
$554.09B
ABBVAbbVie Inc.
$376.54B
UNHUnitedHealth Group Incorporated
$342.24B
MRKMerck & Co., Inc.
$302.33B
Zhongchao Inc. 소개
Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, such as the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves pharmaceutical enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, and doctors. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.
회사 설명은 영어로 표시됩니다.
웹사이트 방문 →